Omer Suhaib, MD
Neurology · Oklahoma City, OKNPI 1336589548
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (52.5%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. UCB, Inc. accounts for 84.1% of it on its own, with 25 other manufacturers making up the rest. 2025 is the largest year on record at $5,616, 6.4 times the $880 reported in 2019.
Across 114 payments — averaging $104.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$10K
- AbbVie$382
- AstraZeneca$242
- Supernus Pharmaceuticals, Inc.$235
- Johnson & Johnson$168
- Mallinckrodt Enterprises LLC$110
- plus $766 from 20 others
What the payments were for
- Consulting fees$3,57030%
- Speaking & faculty fees$6,26952%
- Travel & lodging$851%
- Food & beverage$1,98217%
- Education$360%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 12 | $10,039 |
| AbbVie(2 entities) | 25 | $382 |
| AstraZeneca | 7 | $242 |
| Supernus Pharmaceuticals, Inc. | 14 | $235 |
| Johnson & Johnson | 3 | $168 |
| Mallinckrodt Enterprises LLC | 5 | $110 |
| Novartis | 5 | $107 |
| Sunovion Pharmaceuticals Inc. | 12 | $103 |
| Lundbeck LLC | 3 | $73 |
| Teva Pharmaceuticals USA, Inc. | 5 | $68 |
| Livanova USA, Inc. | 2 | $56 |
| Argenx US, Inc. | 2 | $54 |
| Acorda Therapeutics, Inc | 2 | $39 |
| MDD US Operations, LLC | 2 | $36 |
| Lilly USA, LLC | 2 | $32 |
| Pfizer | 2 | $30 |
| Amneal Pharmaceuticals LLC | 2 | $24 |
| Amgen | 1 | $23 |
| NS Pharma, Inc. | 1 | $20 |
| Biogen | 1 | $20 |
| Genentech USA, Inc. | 1 | $18 |
| Sanofi | 1 | $17 |
| Neurocrine Biosciences, Inc. | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
| Kyowa Kirin, Inc. | 1 | $14 |
| Sumitomo Pharma America, Inc. | 1 | $2 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,942 in reported general payments places this provider in the 70th percentile of 152 neurology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Carbidopa-LevodopaCarbidopa/Levodopa | 15 | $266 |
| Gabapentin | 14 | $148 |
| Prednisone | 29 | $93 |
Paid to pharmacies, not to this prescriber.
Other neurology in Oklahoma City
- Cherian KarunapuzhaOklahoma City$4.1M
- Gabriel PardoOklahoma City$1.5M
- Marguerite ButcheeOklahoma City$324K
- Chelsea BerkleyOklahoma City$277K
- Mariana VargaOklahoma City$183K
- Aaron FarrowOklahoma City$172K
- Ashish MasihOklahoma City$158K
- Christi PendergraftOklahoma City$73K
- Courtney IserOklahoma City$56K
- Jeanne KingOklahoma City$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.